AVOCOM OINT 0.1% 30G

Indications

Approved Uses

Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (e.g., atopic dermatitis and psoriasis).

Off-Label Uses

Off-label examples: seborrheic dermatitis (short courses), chronic hand eczema, lichen simplex chronicus/lichen planus (including oral specialist use), vitiligo (adjunct), alopecia areata (limited evidence).

Dosage & Administration

Dosing by Condition

For corticosteroid-responsive dermatoses (including atopic dermatitis and psoriasis): apply a thin film once daily; avoid routine occlusion, and if used for thick/resistant plaques, occlusion should be short-term and clinician-directed only.

Initial Dose

Apply a thin layer to the affected skin area once daily

Maintenance Dose

Apply a thin film to the affected skin area once daily. Therapy should be discontinued when control is achieved.

Maximum Dose

Apply a thin layer once daily; avoid prolonged continuous use and avoid large-area application-reassess if not improved within ~2 weeks (especially for potent steroids).

Dose Adjustment Notes

Use the lowest effective amount for the shortest duration; once controlled, step down by reducing frequency (e.g., intermittent/alternate-day) or switch to a lower-potency steroid; if no improvement within ~2 weeks, reassess diagnosis/adherence and consider alternative therapy.

How to Take

Topical use: apply a thin film to affected skin once daily and rub in gently; wash hands before and after (unless treating hands); avoid eyes and other mucous membranes; do not apply to face/groin/axillae or broken/infected skin unless directed; avoid occlusive dressings/bandaging unless prescribed.

Side Effects

Common Side Effects

Application-site burning/stinging/tingling, pruritus, dryness/irritation; with prolonged use: skin atrophy, striae, telangiectasia, folliculitis/acneiform eruptions, hypertrichosis, hypopigmentation, perioral dermatitis, secondary infection (rarely furunculosis).

Side Effect Frequency

Common: application-site burning/stinging/itching/irritation; Uncommon/less common: folliculitis/furunculosis, acneiform eruptions, hypopigmentation, allergic contact dermatitis, perioral dermatitis, hypertrichosis, striae/skin atrophy (risk increases with prolonged/occlusive use); Rare: systemic corticosteroid effects including HPA-axis suppression/Cushingoid features, hyperglycemia, and (especially in children) intracranial hypertension.

Safety & Warnings

Warnings & Precautions

Avoid eyes/mucosa and periocular use; do not use under occlusion unless directed; use the minimum effective amount for the shortest duration and avoid large areas; higher systemic-toxicity risk in children; avoid/appropriately treat infected dermatoses; monitor for skin atrophy/striae (especially face/intertriginous areas) and for ocular adverse effects if used near eyes.

Age Restriction

Not recommended in children under 2 years of age.

Drug Interactions

Interaction Severity

MODERATE: Occlusive dressings/large-area use (increases systemic absorption and HPA-axis suppression risk); MODERATE: strong CYP3A4 inhibitors (e.g., ritonavir/cobicistat, ketoconazole/itraconazole) may increase systemic corticosteroid effects if absorption is significant.

Food Interaction

No clinically relevant food interactions for topical mometasone; grapefruit avoidance is not routinely required.

Special Populations

Kidney Impairment

No adjustment needed

Storage & Patient Advice

Overdose

Excessive/prolonged use (especially under occlusion/large areas) may cause local atrophy/striae and systemic effects including HPA-axis suppression/Cushingoid features; management is to stop or taper and provide supportive care, with monitoring for adrenal insufficiency if significant exposure.

Patient Counseling

Apply a thin layer to affected skin once daily (or as prescribed) and use the smallest amount for the shortest duration; avoid eyes/mucosa and wash hands after use; do not use on face/groin/axillae or on broken/infected skin unless directed; avoid occlusive dressings unless prescribed; stop when control is achieved and seek medical advice if worsening, signs of infection, or steroid adverse effects (skin thinning/striae) occur; do not share-this is prescription-only (per SFDA legal status).

Monitoring Requirements

Monitor for local adverse effects (atrophy, striae, telangiectasia, dermatitis, infection) and treatment response; consider HPA-axis suppression monitoring in high-risk use (large surface area, prolonged therapy, occlusion, pediatric patients).

Pharmacology

Mechanism of Action

Topical glucocorticoid: binds intracellular glucocorticoid receptors to alter gene transcription, inducing lipocortins that inhibit phospholipase A2 and reducing prostaglandin/leukotriene production, producing anti-inflammatory, antipruritic, and vasoconstrictive effects.

Onset of Action

Within hours for reduction in itching/redness; noticeable improvement typically within 1-2 days.

Duration of Effect

Approximately 24 hours per application (supports once-daily use); clinical benefit persists with continued daily use.

Bioavailability

Minimal systemic absorption on intact skin without occlusion (typically <1%); absorption increases with inflammation, broken skin, large surface area use, prolonged therapy, or occlusion.

Excretion

After systemic absorption, metabolites are eliminated mainly via bile/feces with a minor renal component (exact proportions after topical use are not well quantified).

Product Information

Available Dosage Forms

Ointment, cream, lotion/solution (topical); nasal spray exists as a separate product/indication (allergic rhinitis).

Composition per Dose

Each gram of ointment: 1 mg mometasone furoate (0.1%) in a white petrolatum base

OTC Alternatives

Hydrocortisone 1% topical (cream/ointment) for mild inflammatory dermatoses; plus non‑steroidal OTC supportive options such as regular emollients/moisturizers (and barrier creams) for dryness/irritation.

Skin Condition

Eczema, Psoriasis

Steroid Potency

Potent

Reviewed by Al Mujtama Pharmacy Medical Review Team. Last reviewed 26-05-2026